US · AVTX
Avalo Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Rockville, MD 20850
- Website
- avalotx.com
Price · as of 2024-12-31
$13.71
Market cap 197.65M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $14.66 | +6.93% |
| Intrinsic Value(DCF) | $7.23 | -47.26% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $283.17 | +1,965.39% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $9,936.00 | ||||
| 2016 | $3,456.00 | $0.00 | $0.00 | ||
| 2017 | $15,580.80 | $381,617.56 | $21,243.07 | $11,406.81 | $4,121,892.60 |
| 2018 | $15,868.80 | $137,271.41 | $0.00 | $0.00 | $81,547.34 |
| 2019 | $8,208.00 | $13,926.64 | $305.17 | $0.00 | $42,367.05 |
| 2020 | $9,763.20 | $9,235.41 | $946.45 | $0.00 | $0.00 |
| 2021 | $1,958.40 | $822.44 | $0.00 | $0.00 | $24,307.47 |
| 2022 | $590.40 | $15,170.58 | $436,192.55 | $0.00 | $0.00 |
| 2023 | $5.88 | $3.34 | $0.00 | $0.00 | $8,789.05 |
| 2024 | $7.76 | $14.66 | $6.91 | $0.00 | $283.17 |
AI valuation
Our deep-learning model estimates Avalo Therapeutics, Inc.'s (AVTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $14.66
- Current price
- $13.71
- AI upside
- +6.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$7.23
-47.26% upside
Graham-Dodd
—
— upside
Graham Formula
$283.17
+1,965.39% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AVTX | Avalo Therapeutics, Inc. | $13.71 | 197.65M | +7% | -47% | — | +1,965% | -1.80 | 0.47 | 143.03 | 1.04 | — | 0.51 | 182.99% | -15535.60% | -7965.76% | -50.06% | 26350.77% | -40.91% | 0.00 | — | 19.96 | 19.42 | 1.96 | -9713.00% | -7708.00% | 5908.00% | -77.77% | -7.05 | 18867.69% | 0.00% | 0.00% | 201.50% | 1.03 | 1.45 | -160.77 | -1.75 |
| AARD | Aardvark Therapeutics, In… | $12.49 | 271.95M | — | — | — | — | -6.35 | -2.39 | — | -2.56 | -3.45 | -2.39 | 0.00% | — | — | 46.03% | 26.47% | -46.77% | -0.01 | — | 15.05 | 14.95 | 2.69 | 18393.00% | — | 21243.00% | -13.91% | -3.67 | 21.14% | 0.00% | 0.00% | 39.22% | -2.54 | -3.18 | — | -0.36 |
| BDTX | Black Diamond Therapeutic… | $2.47 | 140.73M | — | — | — | — | -1.48 | 1.24 | — | -0.35 | — | 1.24 | 0.00% | — | — | -69.67% | -898.81% | -49.55% | 0.27 | — | 4.92 | 4.79 | 0.18 | -3245.00% | — | -666.00% | -60.22% | -3.03 | -710.82% | 0.00% | 0.00% | 0.00% | -0.34 | -0.43 | — | -5.31 |
| CHRS | Coherus Oncology, Inc. | $1.67 | 201.81M | +1,660% | -75% | -94% | +75% | 4.18 | -0.90 | 0.45 | 4.32 | — | -0.64 | 55.97% | -41.83% | 10.68% | -17.52% | -122.98% | 5.29% | -2.04 | -4.11 | 1.21 | 0.88 | 2.36 | -10988.00% | 378.00% | -8833.00% | -17.16% | -0.07 | -22.51% | 0.00% | 0.00% | 196.44% | -2.36 | -12.87 | 0.99 | -4.79 |
| CRBU | Caribou Biosciences, Inc. | $1.90 | 177.59M | +1,241% | -57% | — | +5,094% | -0.70 | 0.41 | 10.48 | 0.48 | -3.59 | 0.41 | 60.71% | -1667.16% | -1491.95% | -47.99% | -243.96% | -40.00% | 0.10 | — | 7.16 | 6.94 | -0.06 | 1957.00% | -7101.00% | 3794.00% | -138.12% | -4.51 | -211.89% | 0.00% | 0.00% | 0.00% | 0.47 | 0.54 | -7.83 | -1.96 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| EPRX | Eupraxia Pharmaceuticals … | $8.18 | 273.87M | — | — | — | — | -5.48 | 4.23 | — | -3.01 | — | 4.23 | 0.00% | — | — | -144.55% | 1233.17% | -93.26% | 0.00 | -44.74 | 11.10 | 10.74 | 0.92 | -3504.00% | — | 4455.00% | -21.32% | -9.67 | 955.80% | 0.00% | 0.00% | 17.10% | -2.78 | -3.59 | — | 19.45 |
| IVA | Inventiva S.A. | $6.49 | 337.36M | +349% | -81% | — | +2,278% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| OBIO | Orchestra BioMed Holdings… | $4.38 | 247.32M | +415% | -61% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
| PRLD | Prelude Therapeutics Inco… | $2.76 | 210M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
- CEO
- Garry A. Neil
- Employees
- 23
- Beta
- 0.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($7.23 ÷ $13.71) − 1 = -47.26% (DCF, example).